Literature DB >> 3459938

The influence of high-dose methotrexate therapy on serum iron.

A Schalhorn, W Wilmanns, G E Koczorek.   

Abstract

After 43 cycles of high-dose methotrexate (MTX), the behavior of serum iron was determined. In virtually all cases, typical changes were demonstrated: 8-12 h after termination of treatment there was a sharp increase in serum iron. After 48-60 h, maximum values of 295% (median) of the pretreatment levels were found. Only when the serum MTX had dropped to 6.6 X 10(-8) M, after 62 h (median), did the serum iron level begin to drop; 72 h after termination of treatment the serum iron level had returned to the pretreatment level in only one, and after 108 h, only in 50% of the patients. The marked and persistent rise in serum iron must be considered a consequence of a powerful inhibitory effect of high-dose methotrexate on erythropoiesis. A possible explanation for the particular sensitivity of erythropoiesis to MTX may be the marked storage of MTX, and in particular MTX polyglutamates, in mature erythrocytes and their progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459938     DOI: 10.1007/BF01713173

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  21 in total

1.  Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexiate, 4-amino-4-deoxy-N-10-methylpteroylglutamyl-gamma-glutamate.

Authors:  S A Jacobs; R H Adamson; B A Chabner; C J Derr; D C Johns
Journal:  Biochem Biophys Res Commun       Date:  1975-04-07       Impact factor: 3.575

2.  "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment.

Authors:  J R Bertino
Journal:  Semin Oncol       Date:  1977-06       Impact factor: 4.929

Review 3.  Ferrokinetics in man.

Authors:  C A Finch; K Deubelbeiss; J D Cook; J W Eschbach; L A Harker; D D Funk; G Marsaglia; R S Hillman; S Slichter; J W Adamson; A Ganzoni; E R Biblett
Journal:  Medicine (Baltimore)       Date:  1970-01       Impact factor: 1.889

4.  [Ferrokinetics: principles, results, indications (author's transl)].

Authors:  A Schalhorn; W Wilmanns
Journal:  Klin Wochenschr       Date:  1981-04-01

5.  Ferrokinetics and erythropoiesis in man: red-cell production and destruction in normal and anaemic subjects.

Authors:  I Cavill; C Ricketts; J A Napier; A Jacobs
Journal:  Br J Haematol       Date:  1977-01       Impact factor: 6.998

6.  Ferrokinetics and erythropoiesis in man: an evaluation of ferrokinetic measurements.

Authors:  C Ricketts; I Cavill; J A Napier; A Jacobs
Journal:  Br J Haematol       Date:  1977-01       Impact factor: 6.998

7.  Effect of high-dose methotrexate with citrovorum factor on human granulopoiesis.

Authors:  W Schremi; H P Lohrmann
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

8.  Methotrexate and methotrexate polyglutamates in human sarcoma metastases after high-dose methotrexate therapy.

Authors:  A Schalhorn; H Sauer; W Wilmanns; G Stupp-Poutot
Journal:  Klin Wochenschr       Date:  1983-11-02

9.  [Detection of methotrexate in human serum. Comparison between an enzymatic and an enzyme-immunologic method].

Authors:  A Schalhorn; W Wilmanns
Journal:  Onkologie       Date:  1980-08

10.  [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].

Authors:  H Sauer; A Schalhorn
Journal:  Onkologie       Date:  1980-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.